12-Dec-2025
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Globe Newswire (Tue, 9-Dec 4:30 PM ET)
Esperion Partner Otsuka Launches NEXLETOL in Japan for the Treatment of Hypercholesterolemia
Globe Newswire (Fri, 21-Nov 8:00 AM ET)
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
Globe Newswire (Wed, 19-Nov 8:00 AM ET)
Globe Newswire (Tue, 18-Nov 7:00 AM ET)
Globe Newswire (Mon, 10-Nov 8:00 AM ET)
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
Globe Newswire (Thu, 6-Nov 6:00 AM ET)
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
Globe Newswire (Tue, 4-Nov 8:00 AM ET)
Esperion to Participate in Jefferies Global Healthcare Conference - London
Globe Newswire (Mon, 3-Nov 8:00 AM ET)
Globe Newswire (Tue, 28-Oct 8:00 AM ET)
Globe Newswire (Mon, 27-Oct 8:00 AM ET)
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Esperion Therapeutics trades on the NASDAQ stock market under the symbol ESPR.
As of December 12, 2025, ESPR stock price declined to $3.85 with 4,841,237 million shares trading.
ESPR has a beta of 2.05, meaning it tends to be more sensitive to market movements. ESPR has a correlation of 0.13 to the broad based SPY ETF.
ESPR has a market cap of $912.72 million. This is considered a Small Cap stock.
Last quarter Esperion Therapeutics reported $87 million in Revenue and -$.16 earnings per share. This fell short of revenue expectation by $-9 million and missed earnings estimates by -$.09.
In the last 3 years, ESPR traded as high as $7.41 and as low as $.69.
The top ETF exchange traded funds that ESPR belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
ESPR has outperformed the market in the last year with a return of +51.0%, while the SPY ETF gained +14.0%. In the last 3 month period, ESPR beat the market returning +35.6%, while SPY returned +4.0%. However, in the most recent 2 weeks ESPR has underperformed the stock market by returning -4.0%, while SPY returned -0.2%.
ESPR support price is $3.89 and resistance is $4.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ESPR shares will trade within this expected range on the day.